Skip to Main Content
Elizabeth Maher, M.D.,  Ph.D.

Elizabeth Maher, M.D., Ph.D.

Professor

Endowed Title
Theodore H. Strauss Professorship in Neuro-Oncology
School
Medical School
Department
Internal Medicine | Neurology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Elizabeth Maher, M.D., Ph.D., is a Professor in the Department of Internal Medicine and the Department of Neurology and a member of the Division of Hematology and Oncology

    There is a major therapeutic benefit in understanding what you’ve got, believing you will do well, and trusting the team that is treating you.

    Originally from Nova Scotia, Canada, Dr. Maher holds a bachelor's degree in biology from Amherst College in Massachusetts, where she graduated cum laude. she completed her postdoctorate degree in physiology at Mcgill University in Montreal. She then earned her medical degree at McGill University. She completed internal medicine residency training at the University of Toronto.

    Dr. Maher completed multiple fellowships during her career. She did fellowships in hematology and oncology and internal medicine at Harvard Medical School, a fellowship in the Hypertension Research Unit at the University of Medicine and Dentistry of New Jersey, a neurology fellowship at the Children's Hospital of Boston, a fellowship in physiology at McGill University, and a fellowship in adult oncology at the Dana-Farber Cancer Institute at Harvard Medical School.

    Certified by the American Board of Internal Medicine in medical oncology, Dr. Maher joined the UT Southwestern faculty in 2006. She is now the Director of Translational Research for the Neuro-Oncology Program at UT Southwestern and the Director of the Crystal Ball Charity Center for Pediatric Brain and Neurological Diseases.

    At UT Southwestern, Dr. Maher is a member of the Supporting Women Achieving Greatness (SWAG) Committee and the Charles Y.C. and Jane Pak Breast Cancer - Bon Initiative Advisory Committee.

    Dr. Maher is a member of several professional societies, including the American Society of Clinical Oncology, the Society of Neuro-Oncology, and the American Association of Cancer Research.

  • Education
    Other Post Graduate Training
    McGill University Faculty of Medicine (1989)
    Graduate School
    McGill University Faculty of Medicine (1989), Physiology
    Medical School
    McGill University Faculty of Medicine (1993)
    Internship/Residency
    University of Toronto Hospitals, Canada (1996), Internal Medicine
    Fellowship
    Dana-Farber Cancer Institute (1999), Hematology Oncology
  • Research Interest
    • Development of improved imaging techniques for brain tumors
    • Primary and metastatic brain tumors
    • Role of altered metabolism in the progression of malignant gliomas.
  • Publications
    Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (Nature Medicine, (2023), 29, 3, (615-622), 10.1038/s41591-022-02141-2)
    Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF Nature medicine 2024 Jan 30 302
    Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
    Cai Q, Li X, Xiong H, Fan H, Gao X, Vemireddy V, Margolis R, Li J, Ge X, Giannotta M, Hoyt K, Maher E, Bachoo R, Qin Z Nature communications 2023 Dec 14
    Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution
    Zhang H, Yu X, Ye J, Li H, Hu J, Tan Y, Fang Y, Akbay E, Yu F, Weng C, Sankaran VG, Bachoo RM, Maher E, Minna J, Zhang A, Li B Cancer Cell 2023 Oct 41 1788-1802.e10
    Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF Nature medicine 2023 Mar 29 615-622
    Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
    Mellinghoff IK, Van Den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, De La Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF New England Journal of Medicine 2023 389 589-601
    Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
    Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Dan TD, Patel TR, Vo D Discover Oncology 2022 Dec 13
    Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients
    Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Lee M, Dan TD, Patel TR, Vo D Frontiers in Oncology 2022 Sep 12
    Primary central nervous system lymphoma: A real-world comparison of therapy access and outcomes by hospital setting
    Patel AM, Ali O, Kainthla R, Rizvi SM, Awan FT, Patel T, Pan E, Maher E, Desai NB, Timmerman R, Kumar KA, Ramakrishnan Geethakumari P Neuro-Oncology Practice 2022 May 9 183-192
    Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate
    Ganji SK, An Z, Tiwari V, Chang Y, Patel TR, Maher EA, Choi C Magnetic resonance in medicine 2022 Mar 87 1150-1164
    Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm
    Askari P, Dimitrov IE, Ganji SK, Tiwari V, Levy M, Patel TR, Pan E, Mickey BE, Malloy CR, Maher EA, Choi C Magnetic resonance in medicine 2021 Oct 86 1818-1828
  • Professional Associations/Affiliations
    • American Society of Clinical Oncology (2001)
    • Society for Neuro-Oncology (2003)